Please assess the completion status of the following clinical trial:

Trial Title: Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of at least one target liver or other intra-abdominal lesion detected by standard staging scans that, in the judgment of Study Investigators, would be amenable to hyperpolarized C-13 pyruvate/metabolic MR imaging: Target lesion must measure \>=1.0 cm in long axis diameter on CT or MRI~* The subject is able and willing to comply with study procedures and provide signed and dated informed consent.~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.~* Adequate organ function, including creatinine \< 1.5 x ULN or estimated creatinine clearance \>=500 mL/min (by the Cockcroft Gault equation) and total bilirubin \<3x upper limit of normal (ULN).~Part B only:~* No prior local therapy to target lesion.~* If patient agrees to optional biopsy:~  * Presence of at least one target lesion amenable to percutaneous tumor biopsy in the judgment of Interventional Radiology~ * No history of bleeding diathesis.~ * Patients on anti-coagulation they must be able to safely stop treatment for purposes of tumor biopsy.~* Planned treatment with agent targeting PI3K/mTOR pathway (either standard of care or investigational agent)~Exclusion Criteria:~* Patients who because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent.~* Patients unwilling or unable to undergo MR imaging, including patients with contra-indications to MRI, such as cardiac pacemakers or non-compatible intracranial vascular clips.~* Metallic implant or device that distorts local magnetic field and compromises the quality of MR imaging.~* Poorly controlled hypertension, defined as systolic blood pressure at study entry greater than 160 mm Hg or diastolic blood pressure greater than 100 mm Hg. The addition of anti-hypertensives to control blood pressure is allowed.~* Congestive heart failure or New York Heart Association (NYHA) status ≥ 2.~* A history of clinically significant EKG abnormalities, including QT prolongation (QTcF \> 500 ms), a family history of prolonged QT interval syndrome, or myocardial infarction (MI) within 6 months of study entry. Patients with rate-controlled atrial fibrillation/flutter will be allowed on study.~* Any condition that, in the opinion of the Principal Investigator, would impair the patient's ability to comply with study procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part A: Feasibility Run-In (Type: EXPERIMENTAL): Patients with advanced solid tumor malignancies with at least one liver metastasis will be enrolled with iterative adjustment of coil design to optimize imaging parameters including spatial resolution and signal-to-noise ratio (SNR) of hyperpolarized pyruvate / lactate within the target metastatic lesion(s).
- Part B: Biomarker Cohort (Type: EXPERIMENTAL): Patients with advanced solid tumor malignancies and the presence of at least one liver metastasis amenable to hyperpolarized C-13 pyruvate metabolic MR imaging who are planning on being treated with agent targeting PI3K/mTOR pathway will be enrolled.

Based on this trial design, predict the completion outcome and termination type (if applicable).